Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the rabbit study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the pig study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in eluates from 100 kDa microdialysis probes intradermally inserted in the rabbit hind leg. Microdialysis was started at t=0 h and four id injections of VEGF-A mRNA injections (50 μ g each) were given at t=1 h. Dotted line indicates Lower Limit of Quantification (LLOQ, 33.4 pg/mL). Two probes were inserted in each rabbit. Values shown are mean ± SEM (n=4).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in microdialysis eluates from 100 kDa microdialysis probes intradermally inserted on the pig (n=3) abdomen. Values presented as individual values in eluate from each probe. Six intradermal VEGF-A mRNA injections (50 μ L each, total 24, 120, or 600 μ g VEGF-A mRNA) were given at t=0 h. At t=1.5 h after the injections, microdialysis was started. Eluates were collected during the time intervals from 1.5 h to 3.5 h, from 3.5 h to 5.5 h, and from 5.5 h to 7.5 h, respectively. Dotted vertical line indicates Lower Limit of Quantification (33.4 pg/mL); eluate samples below LLOQ are depicted as 0.5 ∗ LLOQ=16.7 pg/mL. Six probes were inserted in each pig, two probes per dose except the 120 μ g dose, where only four probes were used to assess human VEGF-A production following injection of 24 or 600 μ g VEGF-A mRNA. The remaining two probes were used to study effects following injection of citrate/saline vehicle.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection, Saline

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Amounts (pg/mg) of human VEGF-A in skin biopsies excised approximately 8 hours after intradermal injection of VEGF-A mRNA in 3 pigs. Each dose was administered as 6 (24 and 600 μ g dose) or 4 (120 μ g dose) separate injections at two different sites in each pig. Hatched data point in the 24 μ g dose, depicted at 0.1 pg/mg, indicating amount below Lower Limit of Quantification (0.28 pg/mg).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection

Journal: PLoS ONE

Article Title: Blue-violet light decreases VEGFa production in an in vitro model of AMD

doi: 10.1371/journal.pone.0223839

Figure Lengend Snippet: VEGFa protein contents in RPE cell lysates (A), after their normalization for each sample to its protein content (B), and after a second normalization with respect to the value measured in the dark control without A2E (C). VEGFa protein levels released in the culture media (D), and after their normalization with respect to the value measured in the dark control without A2E (E). Note that A2E increased both the levels of VEGFa in the cells and the secreted VEGFa whereas blue-violet light (440 nm) suppressed these increases in VEGFa proteins levels. These protein levels were measured by ELISA following 15 h of light exposure with or without pre-incubation in 20 μM A2E. Data are expressed as mean +/- SEM (n = 4) for intracellular content and as mean +/- SEM (n = 8) for secreted VEGFa. Differences between experimental samples were considered to be significant when p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). Stars on the 20 μM columns represent significant differences with the corresponding 0 μM averaged value.

Article Snippet: The Quantikine Human VEGFa Immunoassay (R&D Systems) was used to quantify VEGFa protein levels in cells and the cell culture medium.

Techniques: Control, Enzyme-linked Immunosorbent Assay, Incubation

Journal: PLoS ONE

Article Title: Blue-violet light decreases VEGFa production in an in vitro model of AMD

doi: 10.1371/journal.pone.0223839

Figure Lengend Snippet: RPE cells were loaded with 0 or 20 μM A2E and then the media supplemented with 10 ng/mL recombinant VEGFa before being exposed to light for 18 h. Viability (A) and apoptosis (B) were assessed with the Apolive Glo AssayTM after light exposure following a 6 h rest period in darkness. The number of apoptotic cells was normalized to cell viability to define the density of apoptotic cells in the remaining viable cells at the end of the experiment (C). In the absence of A2E, VEGFa supplementation increased RPE cell viability in the dark and at 400 nm. VEGFa supplementation of A2E-loaded RPE cells decreased viability at 440 and 630 nm. VEGFa supplementation on RPE cells without A2E did not affect apoptosis upon light exposure. By contrast, VEGFa supplementation on A2E-loaded RPE cells increased apoptosis at 440 nm. Data are expressed as the mean +/- SEM (n = 3). Differences between samples were considered to be significant when p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***).

Article Snippet: The Quantikine Human VEGFa Immunoassay (R&D Systems) was used to quantify VEGFa protein levels in cells and the cell culture medium.

Techniques: Recombinant

Journal: Cell Death & Disease

Article Title: USP12 promotes breast cancer angiogenesis by maintaining midkine stability

doi: 10.1038/s41419-021-04102-y

Figure Lengend Snippet: A The relative expression of VEGF-A and VEGF-C in the supernatant of MDA-MB-231 cells overexpressing USP12 was detected by ELISA. B The relative expression of VEGF-A and VEGF-C in the supernatant of MDA-MB-231 cells with USP12 knockdown was detected by ELISA. C , D Migration of HUVECs treated with supernatant from MDA-MB-231 cells with USP12 overexpression ( C ) and USP12 knockdown ( D ). Representative images are shown in the left panel. The quantitative results are shown in the right panel. E , F . Tube formation assay of HUVECs treated with supernatant from MDA-MB-231 cells with USP12 overexpression ( E ) and USP12 knockdown ( F ). Representative images are shown in the left panel. The quantitative results are shown in the right panel. The experiments were repeated three times. ** p < 0.01, *** p < 0.001; mean ± SD.

Article Snippet: Matrigel matrix (356234, Corning), the human VEGF-A ELISA kit (EKO588-96, Boster) and the human VEGF-C ELISA KIT (EKO539-96, Boster) were also used.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Migration, Over Expression, Tube Formation Assay

Journal: Cell Reports Medicine

Article Title: iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer

doi: 10.1016/j.xcrm.2023.101327

Figure Lengend Snippet:

Article Snippet: VEGF , Miltenyi Biotec , Cat# 130-109-386.

Techniques: Recombinant, DNA Extraction, Sequencing, Staining, Flow Cytometry, Cell Stimulation, Software